difference between semaglutide tirzepatide and retatrutide vs vs Compared Semaglutide vs. Tirzepatide vs. Retatrutide

What actually matters in a clinical decision is how those differences play out in real patients

A realistic timeline puts MHRA approval in late 2027 to mid-2028, following expected FDA approval in late 2027

Who qualifies, and what results look like, are individual, and we settle that at the consultation

doi: 10.2337/dc18-0342

Explore GLP-1 shot information for the main cities in Connecticut below, including Bridgeport, New Haven, Stamford, High Ridge, or browse nearby states

Additionally, we ensured that both the non-GLP-1 RA and GLP-1 RA treatment cohorts had similar mean follow-up times (75.9 months, SD = 37.5 and 75.8 months, SD = 37.9, respectively) to control for lead-time bias